tiprankstipranks
Advertisement
Advertisement

ARCT Stock Latest News

ARCT Rating Reiterated at Hold as High-Risk ARCT-032 CF Program Awaits Binary Phase 2 Readout; $9 Price Target Maintained
RatingsARCT Rating Reiterated at Hold as High-Risk ARCT-032 CF Program Awaits Binary Phase 2 Readout; $9 Price Target Maintained
1d ago
ARCT
Arcturus Therapeutics Signals Progress Amid Revenue Slip
PremiumCompany Announcements
Arcturus Therapeutics Signals Progress Amid Revenue Slip
6d ago
ARCT
Myles Minter Reiterates Buy on Arcturus, Citing Strengthened CF Pipeline, Reduced Competitive Pressure, and Rare-Disease Upside
PremiumRatings
Myles Minter Reiterates Buy on Arcturus, Citing Strengthened CF Pipeline, Reduced Competitive Pressure, and Rare-Disease Upside
6d ago
ARCT
Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline
PremiumCompany Announcements
Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline
7d ago
8K
ARCT
Arcturus Therapeutics reports Q1 EPS (95c), consensus ($1.01)
PremiumThe Fly
Arcturus Therapeutics reports Q1 EPS (95c), consensus ($1.01)
7d ago
ARCT
ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
10d ago
ARCT
Cathie Wood Buys the Dip in GeneDx (WGS); Wall Street Sees 142% Upside
Premium
Market News
Cathie Wood Buys the Dip in GeneDx (WGS); Wall Street Sees 142% Upside
1M ago
WGS
ARCT
Arcturus Therapeutics initiated with a Buy at B. Riley
Premium
The Fly
Arcturus Therapeutics initiated with a Buy at B. Riley
2M ago
ARCT
Arcturus Therapeutics price target lowered to $21 from $66 at Canaccord
PremiumThe Fly
Arcturus Therapeutics price target lowered to $21 from $66 at Canaccord
2M ago
ARCT
Regulatory Shifts Cloud Arcturus Therapeutics’ Outlook as FDA Delays KOSTAIVE BLA and Demands New COVID-19 Efficacy Data
PremiumCompany Announcements
Regulatory Shifts Cloud Arcturus Therapeutics’ Outlook as FDA Delays KOSTAIVE BLA and Demands New COVID-19 Efficacy Data
2M ago
ARCT
Arcturus Therapeutics Balances Pipeline Progress With Cash Strain
PremiumCompany Announcements
Arcturus Therapeutics Balances Pipeline Progress With Cash Strain
2M ago
ARCT
Arcturus Therapeutics price target lowered to $25 from $72 at Piper Sandler
PremiumThe Fly
Arcturus Therapeutics price target lowered to $25 from $72 at Piper Sandler
2M ago
ARCT
Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price
PremiumRatingsArcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price
2M ago
ARCT
Validating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating
Premium
Ratings
Validating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating
2M ago
ARCT
Arcturus Therapeutics price target raised to $8 from $7 at Citi
Premium
The Fly
Arcturus Therapeutics price target raised to $8 from $7 at Citi
2M ago
ARCT
Arcturus Therapeutics reports Q4 EPS ($1.03), consensus (76c)
PremiumThe Fly
Arcturus Therapeutics reports Q4 EPS ($1.03), consensus (76c)
2M ago
ARCT
Options Volatility and Implied Earnings Moves Today, March 03, 2026
PremiumMarket News
Options Volatility and Implied Earnings Moves Today, March 03, 2026
2M ago
AZO
BBY
ARCT Earnings this Week: How Will it Perform?
PremiumPre-Earnings
ARCT Earnings this Week: How Will it Perform?
2M ago
ARCT
Arcturus’ ARCT-2304 Flu Vaccine Trial Reaches Phase 1 Finish Line: What Investors Should Watch Next
PremiumCompany Announcements
Arcturus’ ARCT-2304 Flu Vaccine Trial Reaches Phase 1 Finish Line: What Investors Should Watch Next
3M ago
ARCT
Arcturus Therapeutics initiated with a Buy at Roth Capital
PremiumThe FlyArcturus Therapeutics initiated with a Buy at Roth Capital
4M ago
ARCT
Arcturus Therapeutics price target lowered to $7 from $9 at Citi
Premium
The Fly
Arcturus Therapeutics price target lowered to $7 from $9 at Citi
4M ago
ARCT
Arcturus Therapeutics files $500M mixed securities shelf
Premium
The Fly
Arcturus Therapeutics files $500M mixed securities shelf
5M ago
ARCT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >